The firm leverages structurally engineered fatty acid (SEFA) technology to develop new therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases.

This SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.

After extensive in vivo/in vitro profiling, the company’s lead compound, icosabutate, was selected based on its ability to modulate pivotal pathways associated with inflammatory liver disease, including non-alcoholic steatohepatitis (NASH).

Icosabutate is a potent structurally engineered fatty acid, specifically designed to maximize substrate availability for key pathways involved in the pathogenesis of NASH.